Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 916-899-6 | CAS number: -
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
- Principles of method if other than guideline:
- The influence of Bayscript Blaukomponente MDA on embryo-fetal survival and development was assessed in the Han Wistar rat, when administered during the organogenesis and fetal growth phases of pregnancy (Days 6-19 after mating).
Three groups of 22 females received Bayscript Blaukomponente MDA at doses of 100, 330 or 1000 mg/kg/day by oral gavage administration, from Day 6 to 19 after mating. A similarly constituted control group received the vehicle, purified water, at the same volume dose as the treated groups. Animals were killed on Day 20 after mating for reproductive assessment and fetal examination.
Clinical observations, body weight and food consumption were recorded. Adult females were examined macroscopically at necropsy on Day 20 after mating, kidney weights and the gravid uterus weights were recorded. All fetuses were examined macroscopically at necropsy and subsequently by detailed internal visceral examination or skeletal examination, including cartilaginous examination. - GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Reaction mass of lithium sodium 5-amino-3-{[4-(2-{4-[(7-amino-1-hydroxy-3-sulfo-2-naphthyl)diazenyl]-2-sulfophenyl}vinyl)-3-sulfophenyl]diazenyl}-4-hydroxynaphthalene-2,7-disulfonate 2,2'-(methylimino)diethanol (1:1) and 3,3'-[vinylenebis[(3-sulpho-p-phenylene)azo]]bis[6-amino-4-hydroxynaphthalene-2-sulphonic] acid, lithium sodium salt, compound with 2,2'-(methylimino)diethanol and 3,3'-[vinylenebis[(3-sulpho-p-phenylene)azo]]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonic] acid, lithium sodium salt, compound with 2,2'-(methylimino)diethanol
- EC Number:
- 916-916-7
- Molecular formula:
- not available
- IUPAC Name:
- Reaction mass of lithium sodium 5-amino-3-{[4-(2-{4-[(7-amino-1-hydroxy-3-sulfo-2-naphthyl)diazenyl]-2-sulfophenyl}vinyl)-3-sulfophenyl]diazenyl}-4-hydroxynaphthalene-2,7-disulfonate 2,2'-(methylimino)diethanol (1:1) and 3,3'-[vinylenebis[(3-sulpho-p-phenylene)azo]]bis[6-amino-4-hydroxynaphthalene-2-sulphonic] acid, lithium sodium salt, compound with 2,2'-(methylimino)diethanol and 3,3'-[vinylenebis[(3-sulpho-p-phenylene)azo]]bis[5-amino-4-hydroxynaphthalene-2,7-disulphonic] acid, lithium sodium salt, compound with 2,2'-(methylimino)diethanol
- Test material form:
- liquid
- Details on test material:
- Composition: 30.8% (w/w) dyestuff and 69.2% (w/w) water
Purity: 30.8% (w/w) dyestuff
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- Animal Information
Animals
Strain/Species: RccHan™;WIST rat.
Supplier: Envigo RMS Limited.
Number of animals ordered: 96 time mated females.
Spare animals were removed from the study room after treatment commenced.
Duration of acclimation: 5 days before commencement of pairing.
Age of the animals at the
start of the study (Day 1 of
gestation): 11 to 12 weeks old.
Weight range of the animals
at the start of the study
(Day 1 of gestation): 178 to 241 g
Allocation and Identification
Allocation: On arrival (Day 1 of gestation).
Method: Allocation was controlled to prevent any mating male from providing more than one mated female in each treatment group.
Identification of animals: Each animal was assigned a number and identified uniquely within the study by a tail tattoo.
Identification of cages: Each cage label was color-coded according to group and was numbered uniquely with cage and study number, as well as the identity of the occupant.
Animal Care and Husbandry
Environmental Control
Rodent facility: Limited access - to limit entry of external biological and chemical agents and to limit the transference of such agents between rooms.
Air supply: Filtered fresh air which was passed to atmosphere and not recirculated.
Temperature and relative humidity: Monitored and maintained within the range of 20-24ºC and 40-70%.
Lighting: Artificial lighting, 12 hours light : 12 hours dark with simulated periods of dawn and dusk..
Electricity supply: Public supply with automatic stand-by generators.
Animal Accommodation
Cages: Cages comprised of a polycarbonate body with a stainless steel mesh lid (Tecniplast, UK); changed at appropriate intervals.
Cage distribution: The cages constituting each group were blocked by group and mounted in batteries.
Bedding: Solid bottom cages contained softwood based bark-free fiber bedding (JRS Lignocel, Mansfield, UK), which was changed at appropriate intervals each week.
Number of animals per cage: One female.
Environmental Enrichment
Aspen chew block: A soft white untreated wood block; provided to each cage throughout the study and replaced when necessary.
Plastic shelter: Provided to each cage throughout the study and replaced at the same time as the cages.
Diet Supply
Diet: SDS VRF1 Certified pelleted diet (SDS, Special Diet Services, Witham, UK). The diet contained no added antibiotic or other chemotherapeutic or prophylactic agent.
Availability: Non-restricted.
Water Supply
Supply: Potable water from the public supply via polycarbonate bottles with sipper tubes. Bottles were changed three times per week.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- Formulation
Vehicle: Purified water.
Validated concentration range: 1 mg/mL to 100 mg/mL.
Method of preparation: A series of solutions at the required concentrations were prepared by dilution of individual weighings of the test item formulation supplied.
Frequency of preparation: Weekly.
Storage of formulation: Refrigerated (2-8°C).
Test item accounting: Detailed records of compound usage were maintained.
Formulation Analysis
Stability: Before commencement of treatment, the suitability of the proposed mixing procedures was determined and specimen formulations at 1 and 100 mg/mL were analyzed to assess the stability of the test item in the liquid matrix.
Achieved concentration: Samples of each formulation prepared for administration in Weeks 1 and 2 of treatment were analyzed for achieved concentration of the test item. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test item: Bayscript Blaukomponente MDA
EC number: EC 916-916-7
Appearance: Dark blue liquid
Purity: 30.8% (w/w) dyestuff
Purity/weighing factor: The test item is a reaction mass which cannot be separated from water therefore a correction factor was not applied. - Details on mating procedure:
- Time mated females were used.
- Duration of treatment / exposure:
- Females were treated from Day 6 to Day 19 (inclusive) after mating, once daily at approximately the same time each day.
- Frequency of treatment:
- Females were treated from Day 6 to Day 19 (inclusive) after mating, once daily at approximately the same time each day.
- Duration of test:
- Animals were killed on Day 20 after mating for reproductive assessment and fetal examination.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Vehicle
- Dose / conc.:
- 100 mg/kg bw/day
- Remarks:
- Bayscript Blaukomponente MDA
- Dose / conc.:
- 330 mg/kg bw/day
- Remarks:
- Bayscript Blaukomponente MDA
- Dose / conc.:
- 1 000 mg/kg bw/day
- Remarks:
- Bayscript Blaukomponente MDA
- No. of animals per sex per dose:
- 22 female animals per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The dose levels selected for this study are 100, 330 and 1000 mg/kg/day as supplied (active material: 30.8, 102 and 308 mg/kg/day).
In a preliminary rat embryo-fetal survival and development study, administration of Bayscript Blaukomponente MDA to rats by oral gavage during the organogenesis phase of pregnancy (Days 6 to 19 after mating) at 250, 500 and 1000 mg/kg/day (active material: 77, 154 and 308 mg/kg/day) was well tolerated. The no observed adverse effect level (NOAEL) for maternal toxicity and embryo-fetal survival and development was considered to be 1000 mg/kg/day, therefore target doses of 100, 330 or 1000 mg/kg/day were considered acceptable for this study.
Examinations
- Maternal examinations:
- Serial Observations
Clinical Observations
Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment. Cages and cage-trays were inspected daily for evidence of animal ill-health amongst the occupant(s). Any deviation from normal was recorded at the time in respect of nature and severity, date and time of onset, duration and progress of the observed condition, as appropriate.
During the acclimation period, observations of the animals and their cages were recorded at least once per day.
Signs Associated with Dosing
Detailed observations were recorded daily at the following times in relation to dose administration:
Predose observation
As each animal returned to its home cage 1 to 2 hours after completion of dosing As late as possible in the working day
Clinical Signs
A detailed physical examination was performed on each animal on Days 5, 12, 18 and 20 after mating to monitor general health.
Body Weight
The weight of each adult was recorded on Days 1, 3 and 6-20 after mating.
Food Consumption
The weight of food supplied to each adult, that remaining and an estimate of any spilled was recorded for the periods Days 1-2, 3-5, 6-9, 10-13, 14-17 and 18-19 after mating inclusive.
Terminal Investigations
Necropsy
All adult females were subject to a detailed necropsy. After a review of the history of each animal, a full macroscopic examination of the tissues was performed. All external features and orifices were examined visually. Any abnormality in the appearance or size of any organ and tissue (external and cut surface) was recorded and the required tissue samples preserved in appropriate fixative.
Examination included a detailed assessment and documentation of any color changes in the internal organs, adipose tissue or skin. If color changes were observed, representative photographs were taken before retained tissues were placed in fixative.
Schedule Females surviving until the end of the scheduled study period were killed on Day 20 after mating.
Sequence To allow satisfactory inter-group comparison to minimise effects from the timing of the necropsy across groups.
Organ weights
Kidneys were weighed for adult females. - Ovaries and uterine content:
- Reproductive Assessment
For all females surviving to term, the following was recorded:
Uterus Gravid uterine weight (including cervix and ovaries).
The following were recorded for all animals:
For each ovary/uterine horn the number of: Corpora lutea, Implantation sites, Resorption sites (classified as early or late), Fetuses (live and dead).
Apparently non-pregnant animals and for apparently empty uterine horns: The number of uterine implantation sites were checked after staining with ammonium sulphide. - Fetal examinations:
- Fetal Examination and Processing
Examination of all viable fetuses and placentae: Dissected from the uterus, individually weighed and identified within the litter using a coding system based on their position in the uterus. Examined externally with abnormalities recorded. The sex of each fetus was recorded.
Examination of nominally 50% of fetuses in each litter. Sexed internally and eviscerated.
Fixation: Fetuses eviscerated were fixed in Industrial Methylated Spirit (IMS). Remaining fetuses were fixed whole in Bouin’s fluid.
Processing: Bouin’s fixed fetuses were subject to free-hand serial sectioning. IMS fixed fetuses were processed and stained with Alizarin Red and Alcian blue.
Fetal Pathology Examination:
Bouin’s fixed fetuses: Serial sections were examined for visceral abnormalities
Alizarin Red and Alcian blue stained fetuses: Assessed for skeletal and cartilage development and abnormalities. - Statistics:
- A statistical analysis was performed.
- Indices:
- Prenatal losses are separated into pre- and post-implantation phases. Pre-implantation loss was considered to reflect losses due to non-fertilization of ova and failure to implant. It was calculated from the formula:
Pre-implantation loss (%) = [(Number of corpora lutea – Number of implantations): (Number of corpora lutea)] : x 100
Where the number of implantations exceeded the number of corpora lutea observed, pre-implantation loss was assumed to be zero (i.e. no pre-implantation loss was considered to have occurred).
Post-implantation loss was calculated from the formula:
Post-implantation loss (%) = [(Number of implantations – Number of live fetuses): (Number of implantations)] x 100
All group values and SD (as appropriate) were calculated from the individual litter values. - Historical control data:
- The rat was chosen as the test species because of the requirement for a rodent species by regulatory agencies. The RccHan™;WIST strain was used because of the availability of historical control data.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no signs associated with dosing observed, and there were no test item related clinical signs during the detailed weekly physical examination.
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- There were no mortalities.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on bodyweight or gravid uterine weights.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on food consumption.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on body weight adjusted kidney weights on Day 20 of gestation
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Macroscopically, the kidneys of the dams given 330 or 1000 mg/kg/day were dark. This finding was considered to be related to the colour of the test item and therefore considered not to be adverse.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
- Details on results:
- Administration of Bayscript Blaukomponente MDA to rats by oral gavage administration during the organogenesis and fetal growth phase of pregnancy (Days 6-19 after mating) at 100, 330 or 1000 mg/kg/day produced no maternal toxicity.
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- Migrated Data from removed field(s)
Field "Effects on pregnancy duration" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsMaternalAnimals.MaternalDevelopmentalToxicity.EffectsOnPregnancyDuration): no effects observed - Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Other effects:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Details on maternal toxic effects:
- Administration of Bayscript Blaukomponente MDA to rats by oral gavage administration during the organogenesis and fetal growth phase of pregnancy (Days 6-19 after mating) at 100, 330 or 1000 mg/kg/day produced no maternal toxicity.
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: Administration of Bayscript Blaukomponente MDA to rats by oral gavage administration during the organogenesis and fetal growth phase of pregnancy (Days 6-19 after mating) at 100, 330 or 1000 mg/kg/day produced no maternal toxicity.
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- Group mean placental, litter and fetal weights were similar in all groups.
Migrated Data from removed field(s)
Field "Fetal/pup body weight changes" (Path: ENDPOINT_STUDY_RECORD.DevelopmentalToxicityTeratogenicity.ResultsAndDiscussion.ResultsFetuses.FetalPupBodyWeightChanges): no effects observed - Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- There were no test item related effects on any gestation or litter parameters evaluated (implantation rate, pre and post implantation loss, litter size and sex ratio).
- Changes in postnatal survival:
- not examined
- External malformations:
- no effects observed
- Description (incidence and severity):
- There was no adverse effect of maternal treatment on the incidence of major and minor abnormalities and skeletal variants.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- There was no adverse effect of maternal treatment on the incidence of major and minor abnormalities and skeletal variants.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- There was no adverse effect of maternal treatment on the incidence of major and minor abnormalities and skeletal variants.
- Other effects:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Administration of Bayscript Blaukomponente MDA to rats by oral gavage administration during the organogenesis and fetal growth phase of pregnancy (Days 6-19 after mating) at100, 330 or 1000 mg/kg/day produced no maternal toxicity or any effects on embryofetal survival or development.
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remarks'
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Any other information on results incl. tables
Litter data - group mean values on Day 20 of gestation
Dose Group Dose (mg/kg/day) |
Control 1 0 |
MDA 2 100 |
MDA 3 330 |
MDA 4 1000 |
||||||||
Group/ Sex |
Corpora Lutea |
Implantations | Resorptions Early Late Total |
Live Young Male Female Total |
Sex ratio (%M) |
Implantation Loss (%) Pre- Post- |
||||||
| 1F | Mean SD N |
11.7 1.68 21 |
10.4 2.38 21 |
0.9 21 |
0.0 21 |
0.9 21 |
5.0 2.12 21 |
4.5 2.02 21 |
9.5 2.60 21 |
53.3 21 |
1.4 21 |
9.4 21 |
| 2F | Mean SD N |
12.4 1.42 17 |
10.9 2.29 17 |
0.8 17 |
0.0 17 |
0.8 17 |
4.6 2.00 17 |
5.5 2.03 17 |
10.1 2.47 17 |
45.9 17 |
12.6 17 |
8.3 17 |
| 3F | Mean SD N |
11.4 1.70 20 |
10.5 2.16 20 |
0.7 20 |
0.1 20 |
0.8 20 |
4.9 1.90 20 |
4.9 1.87 20 |
9.7 2.36 20 |
50.5 20 |
8.9 20 |
7.2 20 |
| 4F | Mean SD N |
12.0 2.46 21 |
10.1 2.91 21 |
0.5 21 |
0.0 21 |
0.6 21 |
4.1 1.80 21 |
5.4 2.46 21 |
9.5 3.01 21 |
46.1 21 |
17.9 21 |
6.3 21 |
Fetal examinations - major abnormality findings - group incidences
Dose Group Dose (mg/kg/day) |
Control 1 0 |
MDA 2 100 |
MDA 3 330 |
MDA 4 1000 |
||||||||||
Placental Weight |
Litter Weight |
Litter Size |
Male Fetal Weight |
Female Fetal Weight |
Overall Fetal Weight |
|||||||||
| 1F | Mean SD N |
0.52 0.048 21 |
34.96 9.329 21 |
9.48 2.600 21 |
3.79 0.269 21 |
3.63 0.200 21 |
3.71 0.223 21 |
|||||||
| 2F | Mean SD N |
0.53 0.089 17 |
37.77 9.604 17 |
10.12 2.472 17 |
3.83 0.264 17 |
3.68 0.321 17 |
3.75 0.290 17 |
|||||||
| 3F | Mean SD N |
0.53 0.060 20 |
36.20 8.420 20 |
9.70 2.364 20 |
3.82 0.245 20 |
3.68 0.195 20 |
3.75 0.213 20 |
|||||||
| 4F | Mean SD N |
0.55 0.149 21 |
35.84 11.588 21 |
9.52 3 .010 21 |
3.92 0.311 21 |
3.68 0.284 20 |
3.80 0.340 21 |
|||||||
Litter data - group mean values on Day 20 of gestation
Dose Group Dose (mg/kg/day) |
Control 1 0 |
MDA 2 100 |
MDA 3 330 |
MDA 4 1000 |
||||||||||
Fetuses |
Litters |
|||||||||||||
Group Number examined total Number Affected |
1 199 1 |
2* 172 1 |
3 194 1 |
4 200 2 |
1 21 2 |
2* 17 1 |
3 20 1 |
4 21 2 |
||||||
Head Visceral |
Microphthalmia/absent optic nerve |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
|||||
Cervical/Thoracic Visceral |
Dorsally displaced pulmonary trunk Muscular ventricular septal defect Diaphragmatic hernia |
0 0 1 |
0 0 0 |
0 0 1 |
1 1 0 |
0 0 1 |
0 0 0 |
0 0 1 |
1 1 0
|
|||||
Lumbar (and abdominal)/Sacral/Caudal Visceral |
Imperforate anus Anury |
0 0 |
0 0 |
0 0 |
1 1 |
0 0 |
0 0 |
0 0 |
1 1 |
|||||
Note: Individual fetuses/litters may occur in more than one category.
* Litter 28 excluded from group incidences – Suspected Day 21
Fetal examinations - minor skeletal abnormality and variants findings - group incidences
Dose Group Dose (mg/kg/day) |
Control 1 0 |
MDA 2 100 |
MDA 3 330 |
MDA 4 1000 |
||||||||||
Fetuses |
Litters |
|||||||||||||
Group Number examined |
1 100 |
2* 85 |
3 99 |
4 99 |
1 21 |
2* 17 |
3 20 |
4 21 |
||||||
Minor skeletal abnormalities Ribs Sternebrae Costal cartilage Total affected by one or more of the above |
medially thickened/kinked bipartite ossified misaligned ossification sites misaligned hemicentres misshapen branched 1st not connected to sternum partially fused misaligned interrupted 7th not connected to sternum hole in xiphoid branched xiphoid Total affected by one or more of the above |
0 1 2 1 0 0 0 0 1 7 1 4 1 15 |
1 0 2 0 0 1 1 1 0 2 0 1 1 8 |
0 0 1 0 0 0 0 1 0 6 1 4 2 13 |
0 0 0 1 1 0 0 0 1 1 0 4 0 7 |
0 1 2 1 0 0 0 0 1 7 1 3 1 12 |
1 0 2 0 0 1 1 1 0 2 0 1 1 7 |
0 0 1 0 0 0 0 1 0 4 1 4 2 9 |
0 0 0 1 1 0 0 0 1 1 0 4 0 7 |
|||||
Rib and vertebral configuration Cervical rib Cervical vertebrae 13th rib short Number of 14th ribs short Thoracolumbar vertebrae Pelvic girdle Delayed/Incomplete ossification/unossified Cranial Sternebrae Vertebrae cervical |
short supernumerary full supernumerary additional short short supernumerary full supernumerary total 20 unilateral cranial shift unilateral caudal shift cranial centres 5th and/or 6th other total cervical thoracic sacrocaudal |
2 0 0 2 26 0 26 1 0 1 3 33 10 37 0 0 1 |
1 0 0 0 16 1 17 0 1 1 5 13 3 13 0 2 0 |
1 1 1 1 29 1 29 1 0 3 3 7 9 13 0 2 0 |
2 0 0 0 31 0 31 0 0 0 9 12 8 15 1 4 0 |
1 0 0 2 13 0 13 1 0 1 2 17 7 18 0 0 1 |
1 0 0 0 9 1 10 0 1 1 3 6 2 6 0 2 0 |
1 1 1 1 13 1 13 1 0 3 2 5 5 8 0 1 0 |
2 0 0 0 14 0 14 0 0 0 6 8 7 10 1 4 0 |
|||||
Increased ossification Cranial Cervical vertebral centra |
partially fused jugal to maxilla all ossified |
1 19 |
0 14 |
2 18 |
2 10 |
1 9 |
0 6 |
2 10 |
2 7 |
|||||
Note: Individual fetuses/litters may occur in more than one category.
* Litter 28 excluded from group incidences – Suspected Day 21
Fetal examinations - minor visceral abnormality and necropsy findings - group incidences
Dose Group Dose (mg/kg/day) |
Control 1 0 |
MDA 2 100 |
MDA 3 330 |
MDA 4 1000 |
||||||||||
Fetuses |
Litters |
|||||||||||||
Group Number examined Total Number Affected |
1 99 31 |
2* 87 30 |
3 95 29 |
4 101 14 |
1 21 18 |
2* 17 15 |
3 20 16 |
4 20 11 |
||||||
Visceral abnormalities Brain Eyes Thyroid Thymus Azygos vein Diaphragm Liver Kidney(s) Ureter(s) Testis(es) Umbilical artery Haemorrhages Head Abdomen General |
dilated interventricular foramen variation in lens shape small lobe partially undescended lobe thymic remnant dilated thinning with liver protrusion fissured posterior caudate lobe small renal papilla dilated renal pelvis dilated/marked undescended malpositioned left brain abdominal cavity subcutaneous |
0 1 0 9 0 1 1 0 0 0 0 0 2 18 4 0 0 |
3 0 1 1 0 0 0 0 1 0 1 0 0 16 4 5 2 |
0 1 0 9 2 0 0 1 1 1 1 1 2 9 6 1 2 |
0 1 0 2 0 0 1 0 0 0 0 0 0 8 2 2 0 |
0 1 0 6 0 1 1 0 0 0 0 0 2 13 4 0 0 |
2 0 1 1 0 0 0 0 1 0 1 0 0 10 4 5 2 |
0 1 0 8 2 0 0 1 1 1 1 1 2 9 6 1 1 |
0 1 0 2 0 0 1 0 0 0 0 0 0 7 2 2 0 |
|||||
Necropsy observations (external) Skin |
shiny |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
|||||
Note: Individual fetuses/litters may occur in more than one category.
* Litter 28 excluded from group incidences – Suspected Day 21
Applicant's summary and conclusion
- Conclusions:
- Administration of Bayscript Blaukomponente MDA to rats by oral gavage administration during the organogenesis and fetal growth phase of pregnancy (Days 6-19 after mating) at 100, 330 or 1000 mg/kg/day produced no maternal toxicity or any effects on embryofetal survival or development.
Macroscopically, the kidneys of the dams given 330 or 1000 mg/kg/day were dark. This finding was considered to be related to the colour of the test item and therefore considered not to be adverse.
The no observed adverse effect level (NOAEL) for maternal toxicity and embryo-fetal survival and development was considered to be 1000 mg/kg/day. According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified. - Executive summary:
The purpose of this study was to assess the influence of Bayscript Blaukomponente MDA on embryo-fetal survival and development when administered during the organogenesis and fetal growth phases of pregnancy (Days 6-19 after mating) in the Han Wistar rat.
Three groups of 22 females received Bayscript Blaukomponente MDA at doses of 100, 330 or 1000 mg/kg/day by oral gavage administration, from Day 6 to 19 after mating. A similarly constituted control group received the vehicle, purified water, at the same volume dose as the treated groups. Animals were killed on Day 20 after mating for reproductive assessment and fetal examination.
Clinical observations, body weight and food consumption were recorded. Adult females were examined macroscopically at necropsy on Day 20 after mating, kidney weights and the gravid uterus weights were recorded. All fetuses were examined macroscopically at necropsy and subsequently by detailed internal visceral examination or skeletal examination, including cartilaginous examination.
Results
There was an increased incidence of dark kidneys in the treated groups, predominantly those given 330 or 1000 mg/kg/day, when compared with control in females killed on Day 20 of gestation.
Otherwise, there were no effects of treatment on maternal or litter parameters, including external fetal examination.
Conclusion
Administration of Bayscript Blaukomponente MDA to rats by oral gavage administration during the organogenesis and fetal growth phase of pregnancy (Days 6-19 after mating) at 100, 330 or 1000 mg/kg/day produced no maternal toxicity or any effects on embryofetal survival or development.
Macroscopically, the kidneys of the dams given 330 or 1000 mg/kg/day were dark. This finding was considered to be related to the colour of the test item and therefore considered not to be adverse.
The no observed adverse effect level (NOAEL) for maternal toxicity and embryo-fetal survival and development was considered to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
